Financial Analysis: Semler Scientific (SMLR) versus Its Competitors

Semler Scientific (OTCMKTS: SMLR) is one of 47 publicly-traded companies in the “Electromedical equipment” industry, but how does it compare to its rivals? We will compare Semler Scientific to related businesses based on the strength of its institutional ownership, analyst recommendations, risk, dividends, profitability, valuation and earnings.

Volatility & Risk

Semler Scientific has a beta of 0.69, meaning that its share price is 31% less volatile than the S&P 500. Comparatively, Semler Scientific’s rivals have a beta of 1.54, meaning that their average share price is 54% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations and price targets for Semler Scientific and its rivals, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Semler Scientific 0 0 2 0 3.00
Semler Scientific Competitors 187 541 1114 45 2.54

Semler Scientific presently has a consensus price target of $44.00, indicating a potential upside of 41.43%. As a group, “Electromedical equipment” companies have a potential upside of 16.92%. Given Semler Scientific’s stronger consensus rating and higher possible upside, equities analysts clearly believe Semler Scientific is more favorable than its rivals.

Profitability

This table compares Semler Scientific and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Semler Scientific 19.66% -299.31% 84.43%
Semler Scientific Competitors -126.11% -67.54% -20.01%

Valuation & Earnings

This table compares Semler Scientific and its rivals gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Semler Scientific $12.45 million -$1.51 million -111.11
Semler Scientific Competitors $1.16 billion $92.96 million -32.76

Semler Scientific’s rivals have higher revenue and earnings than Semler Scientific. Semler Scientific is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Institutional and Insider Ownership

1.9% of Semler Scientific shares are owned by institutional investors. Comparatively, 43.7% of shares of all “Electromedical equipment” companies are owned by institutional investors. 13.9% of Semler Scientific shares are owned by insiders. Comparatively, 15.5% of shares of all “Electromedical equipment” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Semler Scientific rivals beat Semler Scientific on 8 of the 13 factors compared.

Semler Scientific Company Profile

Semler Scientific, Inc. develops, manufactures, and markets patented products that assist healthcare providers to evaluate and treat patients with chronic diseases in the United States. Its products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient's vascular condition; and WellChec, a multi-test service platform to evaluate patients with various chronic diseases. The company's products serve cardiologists, internists, nephrologists, endocrinologists, podiatrists, and family practitioners, as well as organizations, including healthcare insurance plans, integrated delivery networks, independent physician groups, and companies contracting with the healthcare industry; and other healthcare organizations, such as risk assessment groups and other home healthcare providers. It offers its products through salespersons and distributors. Semler Scientific, Inc. was founded in 2007 and is headquartered in San Jose, California.

Receive News & Ratings for Semler Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Semler Scientific and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply